Serum concentrations of thyroid hormones tetraiodothyronine and triiodothyronine commonly are low after head injury and brain death. Thyroid hormone replacement therapy, however, is a controversial part of donor management. This article reviews publications in which thyroid hormone administration was evaluated in human donors. A classification of the “quality” of study methods used in those publications is presented as part of the data review. No publications support the routine administration of thyroid hormone for all donors. “Rescue” replacement in support of cardiac inotropic function is supported by some studies, but the experimental design of those investigations is not optimal. Thyroid hormone replacement and its dosing should be decided by organ procurement organizations as part of treatment protocols.
Get full access to this article
View all access options for this article.
References
1.
RosendaleJDKauffmanHMMcBrideMA. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation.2003;75:1336–1341.
2.
MontoriVMGuyattGH. What is evidence-based medicine?Endocrinol Metab Clin North Am.2002;31:521–526.
3.
GuyattGHHaynesRBJaeschkeRZ. Users' guides to the medical literature: XXV. Evidence-based medicine: Principles for applying the users' guides to patient care. JAMA.2000;284:1290–1296.
4.
KhanKSter RietGPopayJNixonJKleijnenJ. Stage II: Conducting the review phase 5: Study quality assessment. Available at: http://www.york.ac.uk/inst/crd/report4.htm. Undertaking systematic reviews of research on effectiveness. Centre for Reviews and Dissemination. Cochrane Library, University of York, UK. Accessed March 9, 2004.
5.
NovitzkyDCooperDKCReichartB. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation.1987;43:852–854.
6.
NovitzkyDCooperDKCChaffinJSGreerAEDeBaultLEZuhdiN. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation.1990;49:311–316.
7.
RandellTTHöckerstedtKAV. Triiodothyronine treatment is not indicated in brain-dead multiorgan donors: A controlled study. Transplant Proc.1993;25:1552–1553.
8.
SalimAVassiliuPVelmahosGC. The role of thyroid hormone administration in potential organ donors. Arch Surg.2001;136:1377–1380.
9.
GoarinJPCohenSRiouB. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg.1996;83:41–47.
10.
García-FagesLCCabrerCValeroRManyalichM. Hemodynamic and metabolic effects of substitutive triiodothyronine therapy in organ donors. Transplant Proc.1993;25:3038–3039.
11.
OrlowskiJPSpeesEK. Improved cardiac transplant survival with thyroxine treatment of hemodynamically unstable donors: 95.2% graft survival at 6 and 30 months. Transplant Proc.1993;25:1535.
12.
JeevanandamVToddBRegilloTHellmanSEldridgeCMcClurkenJ. Reversal of donor myocardial dysfunction by triiodothryonine replacement therapy. J Heart Lung Transplant.1994;13:681–687.
13.
JeevanandamV. Triiodothyronine: Spectrum of use in heart transplantation. Thyroid.1997;7:139–145.
14.
RosendaleJDKauffmanHMMcBrideMA. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation.2003;75:482–487.
15.
KellyGS. Peripheral metabolism of thyroid hormones: A review. Altern Med Rev.2000;5:306–333.
16.
FarwellAP. Sick euthyroid syndrome. J Intensive Care Med.1997;12:249–260.
17.
UmpierrezGE. Euthyroid sick syndrome. South Med J.2002;95:506–513.
18.
SugimotoTSakanoTKinoshitaYMasuiMYoshiokaT. Morphological and functional alterations of the hypothalamic-pituitary system in brain death with long term bodily living. Acta Neurochir.1992;115:31–36.
19.
PownerDJHendrichALaglerRGNgRHMaddenRL. Hormonal changes in brain dead patients. Crit Care Med.1990;18:702–708.
20.
KollerJWieserCGottardisM. Thyroid hormones and their impact on the hemodynamic and metabolic stability of organ donors and on kidney graft function after transplantation. Transplant Proc.1990;22:355:357.
21.
KaraylaçinKUmanaJPHarrisonJDBuckelsJACMcMasterPMayerAD. Donor thyroid function does not affect outcome in orthotopic liver transplantation. Transplantation.1994;57:669–672.
22.
MacoviakJAMcDougallIRBayerMFBrownMTazelaarHStinsonEB. Significance of thyroid dysfunction in human cardiac allograft procurement. Transplantation.1987;43:824–826.
23.
SzostekMGaciongZDanielelewiczR. Influence of thyroid function in brain stem death donors on kidney allograft function. Transplant Proc.1997;29:3354–3356.
24.
MariotJSadouneLOJacobF. Hormone levels, hemodynamics, and metabolism in brain dead organ donors. Transplant Proc.1995;27:793–794.
25.
GiffordRRMWeaverASBurgJERomanoPJDemersLMPennockJL. Thyroid hormone levels in heart and kidney cadaver donors. J Heart Transplant.1986;5:249–253.
26.
PownerDJDarbyJM. Management of variations in blood pressure during care of organ donors. Prog Transplant.2000;10:25–32.
27.
PownerDJ. Effects of gene induction and cytokine production in donor care. Prog Transplant.2003;13:9–16.
28.
DujardinKSMcCullyRBWijdicksEF. Myocardial dysfunction associated with brain death: Clinical, echocardiographic, and pathologic features. J Heart Lung Transplant.2001;20:350–357.
29.
BirksEJBurtonPBJOwenVJLatifNNyawoBYacoubMH. Molecular and cellular mechanisms of donor heart dysfunction. Transplant Proc.2001;33:2749–2751.
30.
NovitzkyD. Selection and management of cardiac allograft donors. Curr Opin Cardiol.1996;11:174–182.
31.
TaniguchiSKitamuraSKawachiKDoiYAoyamaN. Effects of hormonal supplements on the maintenance of cardiac function in potential donor patients after cerebral death. Eur J Cardiothorac Surg.1992;6:96–101.
32.
PolikarRBurgerAGScherrerUNicodP. The thyroid and the heart. Circulation.1993;87:1435–1441.
33.
RirieDGButterworthJFRoysterRLMacGregorDAZalogaGP. Triiodothyronine increases contractility independent of β-adrenergic receptors or stimulation of cyclic-3′, 5′-adenosine monophosphate. Anesthesiology.1995;82:1004–1012.
34.
ChenJMCullinaneSSpanierTB. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation.1999;100:244–246.
35.
PennefatherSHBullockREMantleDDarkJH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation.1995;59:58–62.
36.
DimopoulouITsagarakisSAnthiA. High prevalence of decreased cortisol reserve in brain-dead potential organ donors. Crit Care Med.2003;31:1113–1117.
37.
ZaroffJGRosengardBRArmstrongWF. Maximizing use of organs recovered from the cadaver donor: Cardiac recommendations. Circulation.2002;106:836–841.
38.
HuntSABaldwinJBaumgartnerW. Cardiovascular management of a potential heart donor: A statement from the Transplantation Committee of the American College of Cardiology. Crit Care Med.1996;24:1599–1601.
39.
PownerDJDarbyJMKellumJA. Proposed treatment guidelines for donor care. Prog Transplant.2004;14:16–26.
40.
RosendaleJDChabalewskiFLMcBrideMA. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant.2002;2:761–768.
41.
WheeldonDRPotterCDOOduroAWallworkJLargeSR. Transforming the “unacceptable” donor: Outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant.1995;14:732–742.
